Clinical trial
Secondary Adjuvant Long Term Study With Arimidex
NCT00295620 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00295620 |
|---|---|
| Title | Secondary Adjuvant Long Term Study With Arimidex |
| Official title | A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy |
| Acronym | SALSA |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Anastrozole |
| Enrollment | 3,484 |
| Start date | Mar 1, 2004 |
| Primary completion | Jun 30, 2017 |
| Completion | Jun 30, 2017 |
| First posted | Feb 24, 2006 |
| Last update posted | Oct 2, 2019 |
| Countries | Austria |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: